Oral News and Research

RSS

NPS first quarter net loss increases to $10.6 million

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today reported its results for the first quarter of 2012.

4 May 2012

Lexicon to receive funding for LX4211 Phase 2 trial in type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that an independent, non-profit organization will provide funding to support the Phase 2 development of LX4211 in type 1 diabetes.

4 May 2012

CAPE arrests growth of prostate cancer cells and tumors in mice

An over-the-counter natural remedy derived from honeybee hives arrests the growth of prostate cancer cells and tumors in mice, according to a new paper from researchers at the University of Chicago Medicine.

4 May 2012

In run up to ruling on health law, Supreme Court's public approval numbers hit new low

A poll by the Pew Research Center for People and the Press found the court's favorability rating to be 52 percent, the lowest in 25 years.

3 May 2012

HiLo trial sets new gold standard for thyroid cancer treatment

The results of a large Cancer Research UK trial have set a new gold standard for treating thyroid cancer, reducing radiation doses to just one third of the current level, according to research in The New England Journal of Medicine.

3 May 2012

First Edition: May 2, 2012

Today's headlines include a report that House Republican lawmakers want to cut bonuses to states for enrolling low-income kids in Medicaid and the Children's Health Insurance Program.

3 May 2012

Medical Brands' cranberry-based oral capsule granted Class IIa medical device status

Medical Brands has obtained a Class IIa medical device status through the appropriate Competent Authorities for Cranberry-Active, a patented cranberry-based oral capsule clinically shown to support urinary tract health.

2 May 2012

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.

2 May 2012

Ultragenyx reports results from UX001 Phase 1 study on HIBM

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration

2 May 2012

Almac acquires high-speed blister line for new Audubon packaging facility

Almac, a leading provider of contract services to the global pharmaceutical and biotech industries, is pleased to announce the acquisition of a state-of-the-art, high-speed blister line for their new 100,000ft2 US commercial packaging facility in Audubon, PA.

2 May 2012

Non-toxic green tea shampoo to treat dandruff

Dandruff sufferers now have a non-toxic product to treat the condition, says a researcher at Georgia Health Sciences University.

2 May 2012

Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Idera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.

2 May 2012

High-dose glucocorticoids double risk of bacterial infections in children with JIA

Children with juvenile idiopathic arthritis have higher rates of bacterial infection requiring hospitalization, and use of high-dose steroids significantly increases that risk, according to research from the University of Alabama at Birmingham.

2 May 2012

High-dose steroids increase infection risk in children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis (JIA) have higher rates of hospitalized bacterial infection than children without JIA according to an observational study appearing in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

2 May 2012

Kadimastem, Merck Serono enter agreement for MS drug-screening platform

Kadimastem, an Israeli Biotechnology company that develops human pluripotent stem cell-related products, today announced the signing of a five year framework agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

30 Apr 2012

MDGHA, CHAI and Mylan partner to fight childhood deaths caused by diarrhea

Mylan Laboratories Limited, the Indian subsidiary of Mylan Inc., today announced that it has entered into a partnership with the United Nation's Millennium Development Goals Health Alliance (MDGHA) and the Clinton Health Access Initiative (CHAI) to fight childhood deaths caused by diarrhea.

30 Apr 2012

Pharmanest commences SHACT Phase I pharmacokinetic study

Karolinska Development: Pharmanest AB today announced that the first patient has been dosed in an open label pharmacokinetic study with its drug candidate SHACT, a product developed for pain relief in connection with intrauterine device (IUD) insertion.

30 Apr 2012

NCI-funded research to customize treatment for oral cancer patients

The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has awarded a two-year grant to Dr. Brian L. Schmidt, professor of oral and maxillofacial surgery at the NYU College of Dentistry, and Dr. Donna G. Albertson, professor at the UCSF Helen Diller Family Comprehensive Cancer Center. The grant will fund groundbreaking research to customize treatment for oral cancer patients.

30 Apr 2012

Rumors, politics swirl around Supreme Court's much-anticipated health law decision

The Supreme Court this week completed the current term's last oral arguments, and now begins a waiting game for what might be its most anticipated decision in years -- the constitutionality of the health law.

27 Apr 2012

Longer looks: Why we still have faith in physicians

This patient is no fool, and she does't award trust liberally. … Yet, somehow, (Mary) Morse-Dwelley never lost faith in Pellegrini. She'd hear the click of her doctor's shoes in the hallway, see her blond hair and funky glasses, and feel confident that she was in good hands. This, too, represents a broad trend: As we have become better-informed patients, we have grown more cynical about a health care system that is ever more corporate and reliant on technology.

27 Apr 2012